NUWE · Nuwellis, Inc.
$2.85
-0.09 (-3.06%)
At close · Jul 17
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions, including continued operating losses, negative cash flows from operations, an accumulated deficit of $320.9 million, and the need for additional capital to fund ongoing operations and growth initiatives (including the integration of the Rendiatech acquisition), raise substantial doubt about the Company’s ability to continue as a going concern for at least twelve months from the date these financial statements are issued. While management’s plans, including recent financing activities, cost discipline initiatives, and contingency measures, are intended to address these conditions, such plans do not alleviate the substantial doubt.”View the 10-Q filed May 15, 2026
Market Cap
$7.64M
Shares
2,680,752
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
| Filed | Type | Industry | Offering | Sold | Exemptions |
|---|---|---|---|---|---|
| 2024-11-20 | New | Other Health Care | $3,848,286 | $3,848,286 | 06b |
| 2024-09-04 | New | Other Health Care | Indefinite | $0 | 06b |
| 2024-08-02 | New | Other Health Care | Indefinite | $0 | 06b |
| 2023-06-26 | New | Biotechnology | Indefinite | $0 | 06b |
| 2020-05-07 | New | Biotechnology | $1,699,998 | $1,699,998 | 06b |
| 2020-04-08 | New | Biotechnology | $2,226,519 | $2,226,519 | 06b |
| 2020-03-30 | New | Biotechnology | $1,248,418 | $1,248,418 | 06b |
Showing 1–7 of 7 filings